jesper brandgaard joins us on the line thank you very much for joining us this morning. i'd like to ask you initially, why does this acquisition make sense to you in the first place? >> thank you the acquisition is interesting for nordisk. it has an asset that treats a rare bleeding disorder, attp. nor disk works towards hematology for half of the business the area of hematology and rare bleeding disorders is an area we've been in for the last 20 years. we believe we are an effective owner of such an asset we can help globally roll out this asset in a speedily fashion. it will obtain reimbursement from governments around the world. >> sir, i believe it is the second time that an offer has been rejected by ablynx. can we expect a third? >> i think we have decided to lay out to the shareholders that we have made these attempts and that we would like to go into a discussion with the board of directors and i think the shareholders should assess the offer made by nordisk and have a dialogue with the board of the company. we believe that in terms of ablynx, a negotiated transa